Medtronic Inc., Cardiac Rhythm and Heart Failure (CRHF) recalls Cardiac Resynchronization Therapy Defibrillators (CRT-Ds), Compia MRI. Labeled as the following: a. Compia MRI CRT-D DF…
- Recall date
- December 19, 2017
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Recall number
- Z-0583-2018
- FDA classification
- Class I
- Brand / firm
- Medtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
- Sold / distributed
- US Nationwide Distribution.
Why it was recalled
Possible prevention of high and low voltage therapy in Medtronic Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillator (CRT-D).
Class I is the FDA’s most serious recall level: there is a reasonable probability that using this product will cause serious harm or death.
What was recalled
Cardiac Resynchronization Therapy Defibrillators (CRT-Ds), Compia MRI. Labeled as the following: a. Compia MRI CRT-D DF1 (Product No. DTMC1D1); b. Compia MRI Quad CRT-D DF4 (Product No.DTMC1QQ ) Implantable devices that automatically detect and treat episodes of ventricular fibrillation, ventricular tachycardia, fast ventricular tachycardia, and bradyarrhythmia. Some devices can also provide resynchronization therapy, including sequential biventricular pacing (CRT-D devices).
Get recall alerts
Free email alert whenever Medtronic Inc., Cardiac Rhythm and Heart Failure (CRHF) has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Medtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)